FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

September 22, 2026 8:01 AM

Lantheus Holdings (NASDAQ: LNTH) announced that the U.S. Food and Drug Administration has granted final approval for Bravnetsa (lutetium Lu ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found